世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
注射ペン市場：製品タイプ別（使い捨て、再利用可能ペン）、治療法別（糖尿病（インスリン、GLP-1）、成長ホルモン、骨粗鬆症、不妊症、自己免疫疾患、癌）、エンドユーザー別（病院、診療所、在宅医療）、地域別 - 2026年までの世界予測Injection Pen Market by Product Type (Disposable, Reusable Pens), Therapy (Diabetes (Insulin, GLP-1), Growth Hormone, Osteoporosis, Fertility, Autoimmune disease, Cancer), End User (Hospitals, Clinics, Home Care), and Region - Global Forecast to 2026 世界の注射ペン市場は、2021年の376億ドルから2026年には533億ドルに達すると予測され、予測期間中のCAGRは7.2%となります。慢性疾患の有病率の増加、規制当局の承認数の増加、有利な償還や政府の支援、注射ペ... もっと見る
日本語のページは自動翻訳を利用し作成しています。 
サマリー
世界の注射ペン市場は、2021年の376億ドルから2026年には533億ドルに達すると予測され、予測期間中のCAGRは7.2%となります。慢性疾患の有病率の増加、規制当局の承認数の増加、有利な償還や政府の支援、注射ペンの技術的進歩などが市場を牽引する傾向にあります。市場は成長していますが、代替の薬物送達モード、発展途上地域での償還状況の悪さ、注射針への不安などの要因が市場の成長を抑制する傾向にあります。一方で、針刺し事故や注射器の誤用が市場の課題となっています。しかし、市場の機会は、生物製剤の特許切れと新興市場にあります。
製品別では、使い捨てタイプの注射ペンが、予測期間中に最大のシェアを占めています。 タイプ別に見ると、注射ペン市場は再利用可能な注射ペンと使い捨ての注射ペンに分けられます。2020年の世界の注射ペン市場では、使い捨て注射ペンセグメントが最大のシェアを占めています。使い捨て注射ペンセグメントの大きなシェアは、その使いやすさと、カートリッジが内蔵されているため手動でカートリッジを装填する必要がなく、手先の器用さが低下した患者や視覚障害のある患者にとって便利であることに起因します。 治療法別では、糖尿病分野が予測期間中に最も高い成長率を示しています。 注入ペン市場は、治療法に基づいて、糖尿病、成長ホルモン治療、不妊治療、骨粗しょう症、自己免疫疾患、がん、その他の治療法に分類されます。2020年には、糖尿病セグメントが注射ペン市場で最大のシェアを占めました。このセグメントの大きなシェアは、糖尿病の高い有病率、糖尿病患者の間でのインシュリン・ペンに関する意識の高まり、高齢者人口の増加、企業や政府による糖尿病に対する患者支援プログラムの増加、市場でのインシュリン・ペンの入手可能性の高まりなどに起因しています。 糖尿病治療薬の種類別では、GLP-1群が予測期間中に最も高い成長率を示しています。 糖尿病治療用の注射ペン市場は、糖尿病治療の種類に基づいて、インスリンとGLP-1に分けられます。2020年の糖尿病治療用注射ペン市場では、GLP-1セグメントが最も高い成長率を示しています。この市場の成長は、GLP-1の血糖値を下げる効率の高さに起因しています。 エンドユーザー別では、在宅医療分野が予測期間中に最も高い成長率を示しています。 エンドユーザーに基づいて、インジェクションペン市場は、ホームケア設定と病院・診療所に分類されます。2020年には、ホームケア設定セグメントがインジェクションペン市場で最も高い成長率を示しました。高齢者人口の増加、薬剤投与の容易さ、慢性疾患の増加、技術の進歩、有利な償還シナリオなどが、在宅医療環境市場の成長率を押し上げる主な要因となっています。 2020年には、アジア太平洋地域が最も高い成長率を示すと予想される 予測年において、アジア太平洋地域は最高の成長率を示すと予想されています。老人人口の増加、一人当たりの所得の増加、主要市場のプレーヤーによるヘルスケア産業への投資の増加、先進技術への需要の高まり、APACの様々な国での民間病院の農村部への拡大などが、この地域のインジェクションペン市場の成長を促進する主な要因となっています。 主な参加企業の内訳は以下の通りです。 - 企業タイプ別 - Tier1-60%、Tier2-30%、Tier3-10%。 - 企業タイプ別 - Tier1-60%、Tier2-30%、Tier3-10% ・役職別 - Cレベル-30%、ディレクターレベル-50%、その他-20 - 地域別 - 北米-45%、欧州-15%、アジア太平洋-25%、ラテンアメリカ-10%、中東・アフリカ-5 インジェクションペン市場の主要プレイヤー インジェクションペン市場の著名なプレイヤーとしては、Novo Nordisk A/S（デンマーク）、Becton, Dickinson and Company（米国）、Ypsomed Holding AG（スイス）、Sanofi（フランス）、Eli Lilly and Company（米国）、Merck KGaA（ドイツ）、Novartis AG（スイス）、AstraZeneca plc（英国）、F. Hoffmann-La Roche Ltd. （スイス）、Owen Mummie（ドイツ）などが挙げられます。(スイス）、Owen Mumford（英国）、Sulzer Ltd.(スイス)、Sun Pharmaceutical Industries Ltd.(インド)、Pfizer(米国)(インド)、ファイザー(米国)、バイオコン(インド)、ルパン(インド)(インド)、Lupin Ltd.(インド)、Wockhardt Ltd.(インド)、AptarGroup, Inc.(米国)、Gerresheimer AG(ドイツ)などがあります。その他のプレイヤーには、Shaily Engineering Plastics Ltd.(インド)、Bespak Europe.(インド)、Bespak Europe Ltd.(イギリス)、SHL Medical AG(ドイツ)などがあります。(英国)、SHL Medical AG(スイス)、Emperra GmbH(ドイツ)、Nemera France SAS、Companion Medical, Inc.(米国)、江蘇デルフ医療機器有限公司(中国)(中国)である。 調査範囲 当レポートでは、注射ペン市場を分析し、製品タイプ、治療法、エンドユーザー、地域など様々なセグメントに基づいて、同市場の市場規模と今後の成長性を推定することを目的としています。また、市場で入手可能な様々な注射ペン製品の製品ポートフォリオマトリクスも掲載しています。さらに、この市場における主要企業の競争力分析を、企業プロフィール、製品内容、主要な市場戦略とともに掲載しています。 本レポートを購入する理由 本レポートは、既存の企業だけでなく、新規参入者や小規模な企業にとっても、市場の動向を把握するのに役立つでしょう。本レポートを購入した企業は、市場における自社のポジションを強化するために、以下の戦略の1つまたは複数の組み合わせを利用することができます。 本レポートでは、以下の点について分析しています。 - 市場への浸透。世界のインジェクションペン市場のトッププレーヤーが提供する製品ポートフォリオに関する包括的な情報。本レポートでは、この市場を製品タイプ別、治療法別、エンドユーザー別、地域別に分析しています - 製品の強化/革新。世界のインジェクションペン市場における今後の動向や製品の発売についての詳細な洞察 - 市場開拓。製品タイプ、治療法、エンドユーザー、地域別の有利な新興市場に関する包括的な情報 - 市場の多様化新製品や製品の強化、成長地域、最近の開発状況、世界のインジェクションペン市場への投資に関する詳細な情報を提供します。 - 競合他社の評価。世界の注射ペン市場における主要企業の市場シェア、成長戦略、製品提供、競争力のあるリーダーシップマップ、能力などを詳細に評価します。
Summary
The global injection pens market is projected to reach USD 53.3 billion by 2026 from USD 37.6 billion in 2021, at a CAGR of 7.2% during the forecast period. Growing prevalence of chronic diseases, increasing number of regulatory approvals, favourable reimbursement and government support, and technological advancements in injection pens tend to drive the market. Though the market is growing, but factors like alternative drug delivery modes, poor reimbursement scenarios in developing regions and needle anxiety tend to restrain the market growth. Whereas, needle-stick injuries & misuse of injection pens tend to pose a challenge for the market. But, the opportunities for the market lie in the patent expiry of biologics and emerging markets.
Based on product, the disposable injection pen segment holds the largest share during the forecast period. Based on type, the injection pens market is segmented into reusable and disposable injection pens. In 2020, the disposable injection pens segment accounted for the largest share of the global injection pens market. The large share of the disposable injection pens segment can be attributed to their ease of use and the presence of a built-in cartridge which eliminates the need for manually loading the cartridge, making it more convenient for patients with reduced dexterity or visual impairments. Based on therapy, the diabetes segment holds the highest growth rate during the forecast period. Based on therapy, the injection pens market is segmented into diabetes, growth hormone therapy, fertility, osteoporosis, autoimmune diseases, cancer, and other therapies. In 2020, the diabetes segment accounted for the largest share of the injection pens market. The large share of this segment is attributed to the high prevalence of diabetes, increasing awareness about insulin pens among diabetic patients, the rising geriatric population, increased patient support programs by companies & government for diabetes, and the growing availability of insulin pens in the market. Based on diabetes therapy, the in GLP-1 segment holds the highest growth rate during the forecast period. Based on type of diabetes therapy, the injection pens market for diabetes therapy is segmented into insulin and GLP-1. In 2020, the GLP-1 segment accounted for the highest growth rate of the injection pens market for diabetes therapy. The growth in the market can be attributed to the higher efficiency of GLP-1 to reduce the blood sugar levels. Based on end user, the home-care settings segment holds the highest growth rate during the forecast period. Based on end users, the injection pens market is segmented into home care settings and hospitals & clinics. In 2020, the home care settings segment accounted for the highest growth of the injection pens market. The growing geriatric population, ease of drug administration, increasing prevalence of chronic diseases, technological advancements, and favorable reimbursement scenarios are some of the key factors driving the growth rate of the home care settings market. Asia Pacific is expected to grow at the highest rate in 2020 Asia Pacific is expected to grow at the highest rate in the forecast year. The rising geriatric population, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for advanced technologies, and expansion of private-sector hospitals to rural areas in various countries in the APAC are the major factors driving the growth of the injection pen market in this region. Break of primary participants was as mentioned below: • By Company Type – Tier 1–60%, Tier 2–30%, and Tier 3–10% • By Designation – C-level–30%, Director-level–50%, Others–20% • By Region – North America–45%, Europe–15%, Asia Pacific–25%, Latin America- 10%, Middle East and Africa–5% Key players in the Injection pen market Prominent players in the injection pens market include Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), Novartis AG (Switzerland), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK), Sulzer Ltd. (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Pfizer (US), Biocon Ltd. (India), Lupin Ltd. (India), Wockhardt Ltd. (India), AptarGroup, Inc. (US), and Gerresheimer AG (Germany). The other players includes Shaily Engineering Plastics Ltd. (India), Bespak Europe Ltd. (UK), SHL Medical AG (Switzerland), Emperra GmbH (Germany), Nemera France SAS, Companion Medical, Inc. (US), and Jiangsu Delfu Medical Device Co., Ltd. (China). Research Coverage: The report analyzes the injection pen market and aims at estimating the market size and future growth potential of this market based on various segments such as product type, therapy, end user, and region. The report also includes a product portfolio matrix of various injection pen products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies. Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market. This report provides insights into the following pointers: • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global injection pen market. The report analyzes this market by product type, therapy, end user and region • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global injection pen market • Market Development: Comprehensive information on the lucrative emerging markets by product type, therapy, end user and region • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global injection pen market • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global injection pen market. Table of Contents
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27 1.2 MARKET DEFINITION 27 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 27 1.3 MARKET SCOPE 28 1.3.1 MARKETS COVERED 28 1.3.2 YEARS CONSIDERED FOR THE STUDY 29 1.3.3 CURRENCY 29 TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 29 1.4 STAKEHOLDERS 30 1.5 SUMMARY OF CHANGES 30 2 RESEARCH METHODOLOGY 32 2.1 RESEARCH DATA 32 FIGURE 1 RESEARCH DESIGN 32 2.1.1 SECONDARY DATA 33 2.1.1.1 Key data from secondary sources 34 2.1.2 PRIMARY DATA 34 FIGURE 2 PRIMARY SOURCES 34 2.1.2.1 Key data from primary sources 35 2.1.2.2 Key industry insights 36 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 37 2.2 MARKET SIZE ESTIMATION 37 FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 38 FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: SANOFI 38 FIGURE 7 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES: INJECTION PENS MARKET (2020) 39 FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTION PENS MARKET (2021–2026) 40 FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41 FIGURE 10 TOP-DOWN APPROACH 41 2.3 MARKET BREAKDOWN & DATA TRIANGULATION 42 FIGURE 11 MARKET DATA TRIANGULATION METHODOLOGY 42 2.4 MARKET SHARE ANALYSIS 43 2.5 ASSUMPTIONS FOR THE STUDY 43 2.6 RISK ASSESSMENT 43 TABLE 2 RISK ASSESSMENT: INJECTION PENS MARKET 43 2.7 LIMITATIONS 44 2.7.1 METHODOLOGY-RELATED LIMITATIONS 44 2.7.2 SCOPE-RELATED LIMITATIONS 44 3 EXECUTIVE SUMMARY 45 FIGURE 12 INJECTION PENS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 45 FIGURE 13 INJECTION PENS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION) 46 FIGURE 14 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2021 VS. 2026 (USD MILLION) 46 FIGURE 15 INJECTION PENS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 47 FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE INJECTION PENS MARKET 48 4 PREMIUM INSIGHTS 49 4.1 INJECTION PENS MARKET OVERVIEW 49 FIGURE 17 GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 49 4.2 ASIA PACIFIC: INJECTION PENS MARKET, BY THERAPY AND COUNTRY (2020) 50 FIGURE 18 DIABETES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC INJECTION PENS MARKET IN 2020 50 4.3 INJECTION PENS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51 FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE INJECTION PENS MARKET DURING THE FORECAST PERIOD 51 4.4 INJECTION PENS MARKET, BY REGION, 2021–2026 52 FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE GLOBAL INJECTION PENS MARKET IN 2026 52 4.5 INJECTION PENS MARKET: DEVELOPED VS. DEVELOPING MARKETS 52 FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD 52 5 MARKET OVERVIEW 53 5.1 MARKET DYNAMICS 53 FIGURE 22 INJECTION PENS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53 5.1.1 MARKET DRIVERS 54 5.1.1.1 Growing prevalence of chronic diseases 54 FIGURE 23 NUMBER OF PEOPLE WITH CHRONIC DISEASES IN THE US, 1995–2030 (MILLION INDIVIDUALS) 54 FIGURE 24 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040 (MILLION) 55 FIGURE 25 GLOBAL CANCER INCIDENCE, 2015–2040 (MILLION) 55 5.1.1.2 Increasing number of regulatory approvals 55 5.1.1.3 Favorable reimbursement and government support 56 5.1.1.4 Technological advancements in injection pens 56 TABLE 3 MARKET DRIVERS: IMPACT ANALYSIS 57 5.1.2 MARKET RESTRAINTS 57 5.1.2.1 Preference for alternative drug delivery modes 57 5.1.2.2 Poor reimbursement scenario in developing countries 57 5.1.2.3 Needle anxiety 57 TABLE 4 MARKET RESTRAINTS: IMPACT ANALYSIS 58 5.1.3 MARKET OPPORTUNITIES 58 5.1.3.1 Patent expiry of biologics to drive the demand for biosimilars 58 5.1.3.2 Growth opportunities in emerging markets 58 FIGURE 26 DIABETES POPULATION IN DEVELOPING COUNTRIES, 2020 VS. 2040 (MILLION) 59 TABLE 5 RISING INCOME LEVELS IN EMERGING COUNTRIES 59 TABLE 6 MARKET OPPORTUNITIES: IMPACT ANALYSIS 60 5.1.4 MARKET CHALLENGES 60 5.1.4.1 Needlestick injuries and misuse of injection pens 60 TABLE 7 MARKET CHALLENGES: IMPACT ANALYSIS 61 5.2 VALUE CHAIN ANALYSIS 61 FIGURE 27 INJECTION PENS MARKET: VALUE CHAIN ANALYSIS 61 5.3 SUPPLY CHAIN ANALYSIS 62 FIGURE 28 INJECTION PENS MARKET: SUPPLY CHAIN ANALYSIS 63 5.4 PRICING ANALYSIS 63 TABLE 8 PRICING OF INJECTION PENS AVAILABLE IN THE MARKET 64 5.5 ECOSYSTEM MARKET MAP 65 FIGURE 29 INJECTION PENS MARKET: ECOSYSTEM MARKET MAP 65 5.6 PORTER’S FIVE FORCES ANALYSIS 65 TABLE 9 INJECTION PENS MARKET: PORTER’S FIVE FORCES ANALYSIS 65 5.6.1 INTENSITY OF COMPETITIVE RIVALRY 66 5.6.2 BARGAINING POWER OF SUPPLIERS 66 5.6.3 BARGAINING POWER OF BUYERS 66 5.6.4 THREAT OF SUBSTITUTES 66 5.6.5 THREAT OF NEW ENTRANTS 67 5.7 REGULATORY ANALYSIS 67 5.7.1 NORTH AMERICA 67 5.7.1.1 US 67 TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 67 TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 68 5.7.1.2 Canada 68 TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 68 FIGURE 30 CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS 69 5.7.2 EUROPE 69 FIGURE 31 EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES 69 5.7.3 ASIA PACIFIC 70 5.7.3.1 Japan 70 TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 70 5.7.3.2 China 71 TABLE 14 CHINA: REGULATORY BODIES APPOINTED FOR MEDICAL DEVICE APPROVAL 71 TABLE 15 CHINA: CLASSIFICATION OF MEDICAL DEVICES 71 5.7.3.3 India 71 5.8 IMPACT OF COVID-19 ON THE INJECTION PENS MARKET 72 5.9 PATENT ANALYSIS 72 5.9.1 PATENT PUBLICATION TRENDS FOR INJECTION PENS 72 FIGURE 32 PATENT PUBLICATION TRENDS (JANUARY 2011–SEPTEMBER 2021) 73 5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 73 FIGURE 33 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021) 74 FIGURE 34 TOP APPLICANT COUNTRIES/REGIONS FOR INJECTION PEN PATENTS (JANUARY 2011–SEPTEMBER 2021) 75 5.10 TECHNOLOGY ANALYSIS 75 TABLE 16 PEN INJECTORS CLASSIFICATION 75 5.10.1 KEY TECHNOLOGIES 76 5.10.1.1 Dose setting and needle actuation 76 5.10.1.2 Pen injector material 76 5.10.2 COMPLEMENTARY TECHNOLOGIES 76 5.10.2.1 In-built dose and time log 76 5.10.2.2 Wireless connectivity 76 5.10.2.3 Smartpen injectors 77 5.10.2.4 Smart caps and attachments 77 5.10.2.5 Injector temperature monitoring 77 5.10.3 ADJACENT TECHNOLOGIES 78 5.10.3.1 Autoinjectors 78 5.10.3.2 Insulin pumps 78 6 INJECTION PENS MARKET, BY TYPE 79 6.1 INTRODUCTION 80 TABLE 17 INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 80 6.2 DISPOSABLE INJECTION PENS 80 6.2.1 HIGH PATIENT COMPLIANCE AND EASE OF HANDLING TO DRIVE THE ADOPTION OF DISPOSABLE INJECTION PENS 80 TABLE 18 DISPOSABLE INJECTION PENS AVAILABLE IN THE MARKET 81 TABLE 19 DISPOSABLE INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 81 6.3 REUSABLE INJECTION PENS 82 6.3.1 REUSABLE INJECTION PENS TO REGISTER THE HIGHEST GROWTH DUE TO TECHNOLOGICAL ADVANCEMENTS 82 TABLE 20 REUSABLE INJECTION PENS AVAILABLE IN THE MARKET 82 TABLE 21 REUSABLE INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83 7 INJECTION PENS MARKET, BY THERAPY 84 7.1 INTRODUCTION 85 TABLE 22 INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 85 7.2 DIABETES 85 TABLE 23 INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 86 TABLE 24 INJECTION PENS MARKET FOR DIABETES THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 86 7.2.1 INSULIN 87 7.2.1.1 Rising prevalence of diabetes is driving the growth of this market 87 TABLE 25 EXAMPLES OF INSULIN INJECTION PENS 88 TABLE 26 INJECTION PENS MARKET FOR INSULIN THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 88 7.2.2 GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY 89 7.2.2.1 Strong focus of major pharmaceutical companies to introduce GLP-1 drugs to drive market growth 89 TABLE 27 EXAMPLES OF GLP-1 INJECTION PENS 89 TABLE 28 INJECTION PENS MARKET FOR GLP-1 THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 90 7.3 GROWTH HORMONE THERAPY 90 7.3.1 DEVELOPMENT OF SUSTAINED-RELEASE GROWTH HORMONE FORMULATIONS FOR REDUCING INJECTION FREQUENCY TO RESTRAIN THE MARKET GROWTH 90 TABLE 29 EXAMPLES OF INJECTION PENS FOR GROWTH HORMONE THERAPY 91 TABLE 30 INJECTION PENS MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 92 7.4 OSTEOPOROSIS 92 7.4.1 GROWING PREVALENCE OF OSTEOPOROSIS IN GERIATRIC PATIENTS AND WOMEN TO DRIVE MARKET GROWTH 92 TABLE 31 EXAMPLES OF INJECTION PENS FOR OSTEOPOROSIS THERAPY 93 TABLE 32 INJECTION PENS MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 94 7.5 FERTILITY 94 7.5.1 DECREASE IN FERTILITY RATE HAS RESULTED IN THE INCREASED USE OF INJECTION PENS 94 TABLE 33 EXAMPLES OF INJECTION PENS FOR FERTILITY THERAPY 95 TABLE 34 INJECTION PENS MARKET FOR FERTILITY THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 95 7.6 CANCER 96 7.6.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 96 TABLE 35 EXAMPLES OF INJECTION PENS FOR CANCER THERAPY 96 TABLE 36 INJECTION PENS MARKET FOR CANCER THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 97 7.7 AUTOIMMUNE DISEASES 97 7.7.1 DEVELOPMENTS IN THERAPIES AND DELIVERY DEVICES FOR THE TREATMENT OF MS TO BOOST THE MARKET GROWTH 97 TABLE 37 EXAMPLES OF INJECTION PENS FOR MULTIPLE SCLEROSIS AND PSORIASIS THERAPY 98 TABLE 38 INJECTION PENS MARKET FOR AUTOIMMUNE DISEASE THERAPY, BY COUNTRY, 2019–2026 (USD MILLION) 98 7.8 OTHER THERAPIES 99 TABLE 39 INJECTION PENS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026 (USD MILLION) 99 8 INJECTION PENS MARKET, BY END USER 100 8.1 INTRODUCTION 101 TABLE 40 INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 101 8.2 HOME CARE SETTINGS 101 8.2.1 HOME CARE SETTINGS ARE THE LARGEST END USERS OF INJECTION PENS 101 TABLE 41 INJECTION PENS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION) 102 8.3 HOSPITALS & CLINICS 103 8.3.1 GROWING INCIDENCE OF NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES HAVE INCREASED THE DEMAND FOR INJECTION PENS 103 TABLE 42 INJECTION PENS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019–2026 (USD MILLION) 104 9 INJECTION PENS MARKET, BY REGION 105 9.1 INTRODUCTION 106 TABLE 43 INJECTION PENS MARKET, BY REGION, 2019–2026 (USD MILLION) 106 FIGURE 35 EMERGING COUNTRIES ARE EXPECTED TO WITNESS HIGHER GROWTH IN THE FORECAST PERIOD 107 9.2 NORTH AMERICA 107 FIGURE 36 NORTH AMERICA: INJECTION PENS MARKET SNAPSHOT 108 TABLE 44 INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 108 TABLE 45 NORTH AMERICA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 109 TABLE 46 NORTH AMERICA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 109 TABLE 47 NORTH AMERICA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 109 TABLE 48 NORTH AMERICA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 110 9.2.1 US 110 9.2.1.1 The US dominates the North American injection pens market 110 FIGURE 37 TOTAL FERTILITY RATE IN THE US POPULATION (1990-2020) 110 TABLE 49 US: KEY MACROINDICATORS 111 TABLE 50 US: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 112 TABLE 51 US: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 112 TABLE 52 US: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 112 TABLE 53 US: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 113 9.2.2 CANADA 113 9.2.2.1 Unfavorable regulatory processes in Canada to restrain the market growth 113 TABLE 54 CANADA: KEY MACROINDICATORS 114 TABLE 55 CANADA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 114 TABLE 56 CANADA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 115 TABLE 57 CANADA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 115 TABLE 58 CANADA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 115 9.3 EUROPE 116 TABLE 59 EUROPE: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 116 TABLE 60 EUROPE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 117 TABLE 61 EUROPE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 117 TABLE 62 EUROPE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 117 TABLE 63 EUROPE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 118 9.3.1 GERMANY 118 9.3.1.1 High diabetes expenditure and reimbursement for injection pens to drive the market in Germany 118 TABLE 64 GERMANY: KEY MACROINDICATORS 119 TABLE 65 GERMANY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 119 TABLE 66 GERMANY: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 120 TABLE 67 GERMANY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 120 TABLE 68 GERMANY: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 120 9.3.2 FRANCE 121 9.3.2.1 Misuse of injection pens pose a threat to the growth of this market 121 TABLE 69 FRANCE: KEY MACROINDICATORS 121 TABLE 70 FRANCE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 122 TABLE 71 FRANCE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 122 TABLE 72 FRANCE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 122 TABLE 73 FRANCE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 123 9.3.3 UK 123 9.3.3.1 NHS support and access to cost-effective injection pens are likely to drive the market in the UK 123 TABLE 74 UK: KEY MACROINDICATORS 124 TABLE 75 UK: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 124 TABLE 76 UK: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 125 TABLE 77 UK: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 125 TABLE 78 UK: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 125 9.3.4 ITALY 126 9.3.4.1 Regional variation in terms of coverage and benefits to hinder the market growth 126 TABLE 79 ITALY: KEY MACROINDICATORS 126 TABLE 80 ITALY: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 127 TABLE 81 ITALY: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 127 TABLE 82 ITALY: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 127 TABLE 83 ITALY: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 128 9.3.5 SPAIN 128 9.3.5.1 Supportive regulations mandating the use of safety injection pens to boost the growth of the Spanish market 128 TABLE 84 SPAIN: KEY MACROINDICATORS 129 TABLE 85 SPAIN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 129 TABLE 86 SPAIN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 130 TABLE 87 SPAIN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 130 TABLE 88 SPAIN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 130 9.3.6 BENELUX 131 9.3.6.1 Increasing awareness about injection pen devices to drive market growth 131 TABLE 89 BENELUX: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 131 TABLE 90 BENELUX: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 132 TABLE 91 BENELUX: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 132 TABLE 92 BENELUX: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 132 9.3.7 REST OF EUROPE 133 TABLE 93 ROE: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 133 TABLE 94 ROE: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 134 TABLE 95 ROE: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 134 TABLE 96 ROE: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 134 9.4 ASIA PACIFIC 135 FIGURE 38 ASIA PACIFIC: INJECTION PENS MARKET SNAPSHOT 136 TABLE 97 APAC: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 137 TABLE 98 APAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 137 TABLE 99 APAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 137 TABLE 100 APAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 138 TABLE 101 APAC: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 138 9.4.1 JAPAN 138 9.4.1.1 High diabetes incidence and supportive reimbursement policies to drive the market growth in Japan 138 TABLE 102 JAPAN: KEY MACROINDICATORS 139 TABLE 103 JAPAN: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 139 TABLE 104 JAPAN: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 140 TABLE 105 JAPAN: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 140 TABLE 106 JAPAN: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 140 9.4.2 CHINA 141 9.4.2.1 Large patient population and healthcare infrastructure improvements to drive the market growth in China 141 TABLE 107 CHINA: KEY MACROINDICATORS 141 TABLE 108 CHINA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 142 TABLE 109 CHINA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 142 TABLE 110 CHINA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 142 TABLE 111 CHINA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 143 9.4.3 INDIA 143 9.4.3.1 Rising prevalence of obesity to drive market growth 143 TABLE 112 INDIA: KEY MACROINDICATORS 144 TABLE 113 INDIA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 144 TABLE 114 INDIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 145 TABLE 115 INDIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 145 TABLE 116 INDIA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 145 9.4.4 SOUTHEAST ASIA 146 9.4.4.1 Growing awareness about diabetes to drive the adoption of injection pens 146 FIGURE 39 DIABETES PREVALENCE IN SOUTHEAST ASIA (2019) 146 FIGURE 40 HEALTHCARE EXPENDITURE (% OF GDP) IN SOUTHEAST ASIA (2018) 147 FIGURE 41 GERIATRIC POPULATION (% OF THE TOTAL POPULATION), 2019 147 TABLE 117 SOUTHEAST ASIA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 147 TABLE 118 SOUTHEAST ASIA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 148 TABLE 119 SOUTHEAST ASIA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 148 TABLE 120 SOUTHEAST ASIA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 148 9.4.5 REST OF APAC 149 TABLE 121 ROAPAC: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 149 TABLE 122 ROAPAC: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 149 TABLE 123 ROAPAC: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 150 TABLE 124 ROAPAC: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 150 9.5 LATIN AMERICA 150 TABLE 125 LATAM: INJECTION PENS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 151 TABLE 126 LATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 151 TABLE 127 LATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 151 TABLE 128 LATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 152 TABLE 129 LATAM: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 152 9.5.1 BRAZIL 152 9.5.1.1 Brazil dominates the injection pens market in Latin America 152 TABLE 130 BRAZIL: KEY MACROINDICATORS 153 TABLE 131 BRAZIL: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 153 TABLE 132 BRAZIL: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 154 TABLE 133 BRAZIL: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 154 TABLE 134 BRAZIL: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 154 9.5.2 MEXICO 155 9.5.2.1 Increasing incidence of lifestyle-related disorders to drive market growth in Mexico 155 TABLE 135 MEXICO: KEY MACROINDICATORS 155 TABLE 136 MEXICO: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 156 TABLE 137 MEXICO: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 156 TABLE 138 MEXICO: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 156 TABLE 139 MEXICO: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 157 9.5.3 REST OF LATIN AMERICA 157 FIGURE 42 HEALTH EXPENDITURE (% OF GDP) IN LATIN AMERICAN COUNTRIES, 2018 157 TABLE 140 ROLATAM: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 158 TABLE 141 ROLATAM: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 158 TABLE 142 ROLATAM: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 158 TABLE 143 ROLATAM: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 159 9.6 MIDDLE EAST & AFRICA 159 9.6.1 INITIATIVES TO ENHANCE HEALTHCARE ACCESSIBILITY TO SUPPORT MARKET GROWTH 159 TABLE 144 MEA: INJECTION PENS MARKET, BY TYPE, 2019–2026 (USD MILLION) 160 TABLE 145 MEA: INJECTION PENS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 160 TABLE 146 MEA: INJECTION PENS MARKET FOR DIABETES THERAPY, BY TYPE, 2019–2026 (USD MILLION) 160 TABLE 147 MEA: INJECTION PENS MARKET, BY END USER, 2019–2026 (USD MILLION) 161 10 COMPETITIVE LANDSCAPE 162 10.1 OVERVIEW 162 10.2 KEY PLAYER STRATEGIES 162 10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 163 FIGURE 43 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE INJECTION PENS MARKET 163 10.4 MARKET SHARE ANALYSIS 164 FIGURE 44 INJECTION PENS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 164 10.5 MARKET RANKING ANALYSIS OF OEM COMPANIES 165 FIGURE 45 INJECTION PENS MARKET RANKING, BY OEM COMPANY (2020) 165 10.6 COMPANY EVALUATION QUADRANT 166 10.6.1 STARS 166 10.6.2 EMERGING LEADERS 166 10.6.3 PERVASIVE PLAYERS 166 10.6.4 PARTICIPANTS 166 FIGURE 46 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT (2020) 167 10.7 COMPANY EVALUATION QUADRANT FOR START-UPS 168 10.7.1 PROGRESSIVE COMPANIES 168 10.7.2 DYNAMIC COMPANIES 168 10.7.3 STARTING BLOCKS 168 10.7.4 RESPONSIVE COMPANIES 168 FIGURE 47 INJECTION PENS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020) 169 10.8 COMPANY PRODUCT FOOTPRINT 170 TABLE 148 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY TYPE 170 TABLE 149 PRODUCT PORTFOLIO ANALYSIS: INJECTION PENS MARKET, BY THERAPY 171 10.9 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE INJECTION PENS MARKET 173 TABLE 150 GEOGRAPHIC REVENUE MIX: INJECTION PENS MARKET (2020) 173 10.10 COMPETITIVE SCENARIO 174 10.10.1 PRODUCT LAUNCHES 174 TABLE 151 PRODUCT LAUNCHES (JANUARY 2018–SEPTEMBER 2021) 174 10.10.2 OTHER DEVELOPMENTS 175 TABLE 152 OTHER DEVELOPMENTS (JANUARY 2018–SEPTEMBER 2021) 175 11 COMPANY PROFILES 176 11.1 KEY PLAYERS 176 (Business Overview, Products Offered, Recent Developments, and MnM View)* 11.1.1 NOVO NORDISK A/S 176 TABLE 153 NOVO NORDISK A/S: BUSINESS OVERVIEW 176 FIGURE 48 NOVO NORDISK A/S: COMPANY SNAPSHOT (2020) 177 11.1.2 BECTON, DICKINSON AND COMPANY 179 TABLE 154 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 179 FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 180 11.1.3 YPSOMED HOLDING AG 182 TABLE 155 YPSOMED HOLDING AG: BUSINESS OVERVIEW 182 FIGURE 50 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2020) 183 11.1.4 SANOFI 185 TABLE 156 SANOFI: BUSINESS OVERVIEW 185 FIGURE 51 SANOFI: COMPANY SNAPSHOT (2020) 186 11.1.5 ELI LILLY AND COMPANY 188 TABLE 157 ELI LILLY AND COMPANY: BUSINESS OVERVIEW 188 FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020) 189 11.1.6 MERCK KGAA 191 TABLE 158 MERCK KGAA: BUSINESS OVERVIEW 191 FIGURE 53 MERCK KGAA: COMPANY SNAPSHOT (2020) 192 11.1.7 ASTRAZENECA 193 TABLE 159 ASTRAZENECA: BUSINESS OVERVIEW 193 FIGURE 54 ASTRAZENECA: COMPANY SNAPSHOT (2020) 194 11.1.8 F. HOFFMANN-LA ROCHE LTD. 196 TABLE 160 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 196 FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 197 11.1.9 OWEN MUMFORD 198 TABLE 161 OWEN MUMFORD: BUSINESS OVERVIEW 198 11.1.10 SULZER LTD. 199 TABLE 162 SULZER LTD.: BUSINESS OVERVIEW 199 11.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD. 200 TABLE 163 SUN PHARMACEUTICAL INDUSTRIES LTD: BUSINESS OVERVIEW 200 FIGURE 56 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020) 201 11.1.12 PFIZER 202 TABLE 164 PFIZER: BUSINESS OVERVIEW 202 FIGURE 57 PFIZER: COMPANY SNAPSHOT (2020) 203 11.1.13 BIOCON LTD. 204 TABLE 165 BIOCON LTD.: BUSINESS OVERVIEW 204 FIGURE 58 BIOCON LTD.: COMPANY SNAPSHOT (2020) 205 11.1.14 LUPIN LTD. 206 TABLE 166 LUPIN LTD.: BUSINESS OVERVIEW 206 FIGURE 59 LUPIN LTD.: COMPANY SNAPSHOT (2020) 207 11.1.15 WOCKHARDT LTD. 208 TABLE 167 WOCKHARDT LTD.: BUSINESS OVERVIEW 208 FIGURE 60 WOCKHARDT LTD.: COMPANY SNAPSHOT (2020) 208 11.1.16 APTARGROUP, INC. 210 TABLE 168 APTARGROUP, INC.: BUSINESS OVERVIEW 210 FIGURE 61 APTARGROUP, INC.: COMPANY SNAPSHOT (2020) 211 11.1.17 NOVARTIS AG 212 TABLE 169 NOVARTIS AG: BUSINESS OVERVIEW 212 FIGURE 62 NOVARTIS AG: COMPANY SNAPSHOT (2020) 213 11.1.18 GERRESHEIMER AG 214 TABLE 170 GERRESHEIMER AG: BUSINESS OVERVIEW 214 FIGURE 63 GERRESHEIMER AG: COMPANY SNAPSHOT (2020) 215 11.2 OTHER PLAYERS 216 11.2.1 SHAILY ENGINEERING PLASTICS LTD. 216 TABLE 171 SHAILY ENGINEERING PLASTICS LTD.: BUSINESS OVERVIEW 216 11.2.2 BESPAK EUROPE LTD. 217 TABLE 172 BESPAK EUROPE LTD.: BUSINESS OVERVIEW 217 11.2.3 SHL MEDICAL AG 218 TABLE 173 SHL MEDICAL AG: BUSINESS OVERVIEW 218 11.2.4 EMPERRA GMBH 219 TABLE 174 EMPERRA GMBH: BUSINESS OVERVIEW 219 11.2.5 NEMERA FRANCE SAS 220 TABLE 175 NEMERA FRANCE SAS: BUSINESS OVERVIEW 220 11.2.6 COMPANION MEDICAL, INC. 221 TABLE 176 COMPANION MEDICAL, INC.: BUSINESS OVERVIEW 221 11.2.7 JIANGSU DELFU MEDICAL DEVICE CO., LTD. 222 TABLE 177 JIANGSU DELFU MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW 222 * Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies. 12 APPENDIX 223 12.1 DISCUSSION GUIDE 223 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227 12.3 AVAILABLE CUSTOMIZATIONS 229 12.4 RELATED REPORTS 229 12.5 AUTHOR DETAILS 231
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（在宅・地域医療）の最新刊レポート
MarketsandMarkets 社の最新刊レポート
本レポートと同じKEY WORD（cancer）の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/19 10:28 144.64 円 160.77 円 193.27 円 |
